Here’s what you should know:
1. Stivarga is for hepatocellular carcinoma patients who were previously treated with Nexavar.
2. The FDA approved Stivarga in April 2017. Japan’s regulatory agency also approved the treatment.
3. Stivarga was found to be safe in a clinical trial.
4. In the clinical trial:
- Median overall survival was 10.6 months for Stivarga patients and 7.8 months for patients on a placebo
- Median progression-free survival rate for patients on Stivarga was 3.1 months compared to 1.5 months for patients on a placebo
- Overall response rate for Stivarga patients was 11 percent, compared to 4 percent for patients on a placebo
More articles on gastroenterology:
Ironwood Pharmaceuticals reports Q2 revenues of $65.1M — 4 insights
GI center to know: Gastro Group & EndoCenter
GI leader to know: Dr. Anthony Albright of Gastro Group & EndoCenter
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
